{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:41:51Z","timestamp":1773286911239,"version":"3.50.1"},"reference-count":10,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T00:00:00Z","timestamp":1436313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:p>Amylin is co\u2010secreted with insulin and is therefore lacking in patients with type 1 diabetes. Replacement with fixed ratio co\u2010administration of insulin and the amylin analogue pramlintide may be superior to separate dosing. This concept was evaluated in a ratio\u2010finding study. Patients with type 1 diabetes were enrolled in a randomized, single\u2010masked, standard breakfast crossover study using regular human insulin injected simultaneously with pramlintide 6, 9 or 12 mcg\/unit insulin or placebo. Insulin dosage was reduced by 30% from patients' usual estimates. Plasma glucose, glucagon and pramlintide and adverse events were assessed. All ratios reduced 0\u20133\u2010h glucose and glucagon increments by &gt;50%. No hypoglycaemia occurred. Adverse events were infrequent and generally mild. All pramlintide\/insulin ratios markedly and safely reduced glycaemic excursions and suppressed glucagon secretion in the immediate postprandial state. Further study using one of these ratios to explore the efficacy and safety of longer\u2010term meal\u2010time and basal hormone replacement is warranted.<\/jats:p>","DOI":"10.1111\/dom.12504","type":"journal-article","created":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T06:58:04Z","timestamp":1433401084000},"page":"904-907","source":"Crossref","is-referenced-by-count":30,"title":["Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes"],"prefix":"10.1111","volume":"17","author":[{"given":"M. C.","family":"Riddle","sequence":"first","affiliation":[{"name":"Department of Medicine Oregon Health &amp; Science University  Portland OR USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. C. J.","family":"Yuen","sequence":"additional","affiliation":[{"name":"Swedish Pituitary Center  Seattle WA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. W.","family":"de Bruin","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gaithersburg MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Herrmann","sequence":"additional","affiliation":[{"name":"AstraZeneca  San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Xu","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gaithersburg MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"\u00d6hman","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gaithersburg MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. G.","family":"Kolterman","sequence":"additional","affiliation":[{"name":"Consultant  La Jolla CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,7,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00404025"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612013397357"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00060793-199708000-00006"},{"key":"e_1_2_7_5_1","unstructured":"AstraZeneca Pharmaceuticals LP.Symlin\u00ae (pramlintide acetate) injection\u00a0\u2013\u00a0prescribing information(revised February2015). Available from URL:http:\/\/www.azpicentral.com\/symlin\/pi_symlin.pdf#page&#x0003D;1. Accessed 19 March 2015."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2004.01319.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.4.724"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3074"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12352"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0042"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2013.0054"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12504","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.12504","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.12504","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:54:11Z","timestamp":1761890051000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,8]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1111\/dom.12504"],"URL":"https:\/\/doi.org\/10.1111\/dom.12504","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,8]]}}}